aTyr Pharma, Inc. (ATYR) — Cash Flow-to-Debt Ratio
aTyr Pharma, Inc. (ATYR) has a Cash Flow-to-Debt Ratio of -0.45x as of December 2025, meaning its operating cash flow of $-12.20 Million could theoretically repay 0% of its total liabilities ($26.88 Million) in one year. See aTyr Pharma, Inc. financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
aTyr Pharma, Inc. Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for aTyr Pharma, Inc. across 14 annual periods. For the full cash flow conversion analysis, see aTyr Pharma, Inc. (ATYR) cash flow conversion.
Annual Cash Flow-to-Debt Ratio for aTyr Pharma, Inc. (2012–2025)
Year-by-year debt coverage analysis for aTyr Pharma, Inc.. Check ATYR cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.31x | $-61.99 Million | $26.88 Million | ▲ +9.9% |
| 2024 | -2.56x | $-69.12 Million | $27.00 Million | ▼ -132.6% |
| 2023 | -1.10x | $-33.22 Million | $30.18 Million | ▲ +35.6% |
| 2022 | -1.71x | $-41.89 Million | $24.50 Million | ▲ +66.9% |
| 2021 | -5.16x | $-33.08 Million | $6.41 Million | ▼ -144.2% |
| 2020 | -2.11x | $-15.30 Million | $7.24 Million | ▼ -60.1% |
| 2019 | -1.32x | $-20.01 Million | $15.16 Million | ▲ +18.9% |
| 2018 | -1.63x | $-31.06 Million | $19.10 Million | ▲ +3.6% |
| 2017 | -1.69x | $-42.36 Million | $25.11 Million | ▲ +43.4% |
| 2016 | -2.98x | $-52.86 Million | $17.72 Million | ▼ -18.5% |
| 2015 | -2.52x | $-36.80 Million | $14.62 Million | ▼ -1130.8% |
| 2014 | -0.20x | $-22.82 Million | $111.65 Million | ▼ -25.0% |
| 2013 | -0.16x | $-17.31 Million | $105.87 Million | ▲ +87.5% |
| 2012 | -1.30x | $-11.38 Million | $8.73 Million | — |